SCHEMBL4599009

SCHEMBL4599009

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](Cc1ccc(NC(=O)OC(C)(C)C)cc1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ IDO1 P14902 2/20 0.40
▸ MDM2 Q00987 1/20 0.40
▸ CYP17A1 P05093 1/20 0.39
▸ DRD2 P14416 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ GLS O94925 1/20 0.38
▸ ITGB3 P05106 1/20 0.37
▸ ITGB1 P05556 1/20 0.37
▸ ITGAV P06756 1/20 0.37
▸ ITGA2B P08514 1/20 0.37
▸ ITGB5 P18084 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ ATM Q13315 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ ADAMTS4 O75173 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19899292 0.89 ATM (0.41) ATMACE
SCHEMBL1062783 0.86 SLC7A5 (0.38) PPARGPPARAITGB1PTPN1ATM
SCHEMBL5407004 0.84 CTRB1 (0.40) PPARGPPARAITGB1
SCHEMBL4600067 0.84 CTRB1 (0.40) PPARGPPARAITGB1
SCHEMBL4600752 0.84 CTRB1 (0.40) PPARGPPARAITGB1
SCHEMBL30510366 0.84 CTRB1 (0.40) PPARGPPARAITGB1
SCHEMBL4600305 0.84 PPARG (0.39) PPARGPPARAITGB3ITGB1ITGA2B
SCHEMBL1063197 0.84 PPARG (0.39) PPARGPPARAITGB3ITGB1ITGA2B
SCHEMBL4599268 0.83 ITGA4 (0.35) PPARGPPARAITGB1PTPN1ATM
SCHEMBL4600014 0.83 ITGA4 (0.35) PPARGPPARAITGB1PTPN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-17 — — US disclosed
WO-2008080223-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-10 — — WO disclosed
EP-1910279-A2 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2008-04-16 — — EP disclosed
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2007-01-25 — — US disclosed
WO-2007002639-A2 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2007-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF HAVCR2, ADAR, NSUN2 PPARG 810/4885PPARA 448/4885IDO1 3619/4885
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE POLQ, POLI, POLH PPARG 499/4885PPARA 480/4885IDO1 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback